{"id":"placebo-in-combination-with-epirubicin","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL417","moleculeType":"Small molecule","molecularWeight":"543.53"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"In this phase 3 trial, placebo serves as the inactive control comparator to epirubicin, an anthracycline chemotherapy agent. Epirubicin works by intercalating into DNA and inhibiting topoisomerase II, leading to DNA damage and cell death in rapidly dividing cancer cells. The placebo arm allows assessment of epirubicin's true clinical benefit over no active treatment.","oneSentence":"Placebo has no pharmacological mechanism; this is a control arm in a clinical trial comparing epirubicin efficacy.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:27:44.931Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cancer indication under investigation in phase 3 trial (specific indication not publicly detailed)"}]},"trialDetails":[{"nctId":"NCT04872985","phase":"PHASE2","title":"Pyrotinib Plus Neoadjuvant Chemotherapy in HR+/HER2-, HER4-High Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2021-04-20","conditions":"Breast Cancer, Hormone-receptor Positive Breast Cancer","enrollment":140},{"nctId":"NCT01358877","phase":"PHASE3","title":"A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-11-08","conditions":"Breast Cancer","enrollment":4804},{"nctId":"NCT03725059","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-12-27","conditions":"Breast Cancer","enrollment":1240},{"nctId":"NCT02897700","phase":"PHASE1","title":"A Randomized Trial of Chemotherapy in Surgical Patients With Infiltrating Ductal Carcinoma of Breast","status":"RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2013-01","conditions":"Breast Cancer","enrollment":300},{"nctId":"NCT02586025","phase":"PHASE3","title":"Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2016-03-14","conditions":"Breast Cancer","enrollment":329},{"nctId":"NCT04490993","phase":"PHASE3","title":"Safety and Efficacy of APL-1202 in Combination With Epirubicin Hydrochloride Versus Epirubicin Hydrochloride Alone in Intermediate and High-risk Chemo-refractory Non-muscle Invasive Bladder Cancer (NMIBC) Patients","status":"UNKNOWN","sponsor":"Jiangsu Yahong Meditech Co., Ltd aka Asieris","startDate":"2017-03-30","conditions":"Non-muscle Invasive Bladder Cancer","enrollment":359},{"nctId":"NCT05121350","phase":"PHASE3","title":"A Clinical Trial to Evaluate the Efficacy and Safety of Anotinib Hydrochloride Capsule Combined With Epirubicin Hydrochloride Versus Placebo Combined With Epirubicin Hydrochloride in First-line Treatment of Advanced Soft Tissue Sarcoma","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2022-03","conditions":"Soft Tissue Sarcoma","enrollment":256},{"nctId":"NCT02468739","phase":"PHASE3","title":"Effect of GM1 in Prevention of Taxanes Induced Neurotoxicity in Operable Breast Cancer","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2015-05","conditions":"Breast Cancer","enrollment":206},{"nctId":"NCT01220128","phase":"PHASE2","title":"Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2011-04-11","conditions":"Neoplasms, Breast","enrollment":66},{"nctId":"NCT02685059","phase":"PHASE2","title":"Addition of PD-L1 Antibody MEDI4736 to a Taxane-anthracycline Chemotherapy in Triple Negative Breast Cancer","status":"COMPLETED","sponsor":"GBG Forschungs GmbH","startDate":"2016-06","conditions":"Breast Cancer","enrollment":174},{"nctId":"NCT04301739","phase":"PHASE3","title":"to Evaluate Efficacy and Safety of HLX10 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versus Placebo as Adjuvant Therapy in Patients With Triple Negative Breast Cancer (TNBC)","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2020-04-17","conditions":"Triple Negative Breast Cancer","enrollment":522},{"nctId":"NCT03756090","phase":"NA","title":"The Combination of Palbociclib With ddEC-P as Neoadjuvant Therapy in Triple Negative Breast Cancer","status":"UNKNOWN","sponsor":"Zhejiang Cancer Hospital","startDate":"2018-12-01","conditions":"Breast Cancer, Breast Diseases, Breast Neoplasms","enrollment":100},{"nctId":"NCT00262067","phase":"PHASE3","title":"A Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy in Untreated Metastatic Breast Cancer (RIBBON 1)","status":"UNKNOWN","sponsor":"Genentech, Inc.","startDate":"2005-12","conditions":"Metastatic Breast Cancer","enrollment":1237},{"nctId":"NCT01433562","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of DLBS1425 as Neoadjuvant in Stage II or III Breast Cancer Patients","status":"COMPLETED","sponsor":"Dexa Medica Group","startDate":"2011-08","conditions":"Breast Cancer","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":44,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo in combination with Epirubicin","genericName":"Placebo in combination with Epirubicin","companyName":"Jiangsu Yahong Meditech Co., Ltd aka Asieris","companyId":"jiangsu-yahong-meditech-co-ltd-aka-asieris","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Placebo has no pharmacological mechanism; this is a control arm in a clinical trial comparing epirubicin efficacy. Used for Cancer indication under investigation in phase 3 trial (specific indication not publicly detailed).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}